4D Molecular Therapeutics (FDMT) Net Income Growth (3y) (2023 - 2026)

4D Molecular Therapeutics (FDMT) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 9.16%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.43%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -3.84%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 79.26%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 4D Molecular Therapeutics 706.51 Mn 315.62 Mn - -24.41%

Historic Data

Download Data
DateValue
Mar 31, 2026 -24.41%
Dec 31, 2025 37.42%
Sep 30, 2025 -21.98%
Jun 30, 2025 -37.97%
Mar 31, 2025 -14.28%
Dec 31, 2024 -24.37%
Sep 30, 2024 -17.93%
Jun 30, 2024 -61.48%
Mar 31, 2024 3.12%
Dec 31, 2023 34.47%
Sep 30, 2023 -54.99%
Jun 30, 2023 -50.19%
Mar 31, 2023 -55.35%